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The World Health Organization (WHO) Global Monitoring Framework includes a set of 
nine voluntary noncommunicable disease goals for 2025.1 It was endorsed by the World 
Health Assembly in 2013 and includes for the first time a shared target to reduce the 
prevalence of raised blood pressure (BP; ≥140/90 mm Hg) globally by 25% by 2025. Other 
related priorities include reducing salt intake by 30% and physical inactivity by 10%.
Hypertension affects 1 billion people worldwide and one third of adults have the condition. 
In addition to a significant increase in morbidity and mortality, the economic impact of 
suboptimal BP control is substantial. Reasons for poor BP control are many, ranging from 
poor medication adherence as a result of drug cost and complex medication regimens, to an 
inability to deliver effective treatment because of inadequate patient medical care, initial 
access, and follow-up, to complicated treatment algorithms for providers to follow.
To address these issues, the Centers for Disease Control and Prevention (CDC), Pan 
American Health Organization, and other major stakeholder organizations are collaborating 
on the Global Standardized Hypertension Treatment Project.2 The Project aims to 
standardize and simplify the treatment of hypertension through the development of a 
framework that is flexible and has worldwide applicability. In Latin America and the 
Caribbean, regional workshop participants developed a primary core set of medications 
appropriate for the treatment of most adults with the condition. They include a diuretic 
(chlorthalidone), angiotensin-converting enzyme inhibitor (lisinopril), angiotensin receptor 
blocker (losartan), calcium channel blocker (amlodipine), b-blocker (bisoprolol), and a 
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mineralocorticoid antagonist (spironolactone). Additional combination pharmacologic 
regimens were developed as well. Mechanisms to increase the availability and affordability 
of these medications in the region are also being pursued.
Other Project aims are to identify and promote the integration of specific key evidence–
based healthcare delivery elements that are central to improving hypertension control. 
Examples are patient registries, standardized treatment protocols, the promotion of 
multidisciplinary team–based care, and patient self-management.
For the first time, the WHO has specific targets to address noncommunicable diseases and 
raised BP, in particular, as a worldwide health priority. Towards this end, the introduction of 
a global standardized treatment approach to hypertension has great potential to enhance BP 
treatment and control worldwide.
References
1. World Health Organization. NCD Global Monitoring Framework; Ensuring progress on 
noncommunicable diseases in countries. http://www.who.int/nmh/global_monitoring_framework/
en/. Accessed June 25, 2014
2. US Centers for Disease Control and Prevention. The Global Standardized Hypertension Treatment 
Project: Identification of a Core Set of medications and Care Delivery Models for the Medical 
Treatment of Hypertension. 2013. http://www.cdc.gov/globalhealth/ncd/pdf/gshtp_march2013.pdf. 
Accessed June 25, 2014
Cohen et al. Page 2
J Clin Hypertens (Greenwich). Author manuscript; available in PMC 2017 December 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
